Skip to main content

Table 4 Association of the intrinsic subtypes with chemotherapy response across the various pathology-based groups

From: Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

 

All patients

Luminal A

Luminal B

HER2-enriched

Basal-like

P value*

 

n

pCR

n

pCR

n

pCR

n

pCR

n

pCR

 

All subgroups

838

23 %

281

6 %

168

16 %

93

37 %

296

38 %

<0.001

HR+/HER2–

451

12 %

239

5 %

143

15 %

25

16 %

44

36 %

<0.001

HER2+

76

34 %

16

0 %

12

33 %

36

42 %

12

58 %

0.011

HR–/HER2– (TN)

292

37 %

19

26 %

8

0 %

30

47 %

235

37 %

0.011

  1. *Likelihood ratio tests: adjusting clinical features: age, clinical stage, clinical nodal status and study cohort. Hormone receptors status and HER2 status were also included in “all subgroups”
  2. pCR, Pathological complete response; ER, Estrogen receptor; PR, Progesterone receptor
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us